Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 05, 2024

BUY
$32.76 - $39.56 $687 - $830
21 Added 210.0%
31 $1.08 Million
Q4 2023

Feb 01, 2024

BUY
$14.5 - $38.0 $145 - $380
10 New
10 $385,000

Others Institutions Holding INBX

About Inhibrx, Inc.


  • Ticker INBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,057,700
  • Market Cap $606M
  • Description
  • Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...
More about INBX
Track This Portfolio

Track Gamma Investing LLC Portfolio

Follow Gamma Investing LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gamma Investing LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gamma Investing LLC with notifications on news.